shRNA/miRNA/gRNA rAAV Production Full Service, Medium Scale


  • Catalog #: SL100871
  • Unit Size: 0.2 mL (>1013 VG/mL)

shRNA/miRNA/gRNA rAAV Production Full Service, Medium Scale

Features:
- Excellent gene delivery efficiency in most cell types including dividing and non-dividing or primary cells.
- Multiple serotypes
(AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-8, AAV-9, AAV-DJ/8 and AAV-DJ).
- Persistent transgene expression.
- Induce efficient gene silencing.

Large shRNA/miRNA/gRNA AAV cis vector inventory for constructing AAV cis plasmid with a specific promoter and reporter:

 
  For Conventional shRNA/miRNA/TuD rAAV Production

 Single-promoter shRNA/miRNA AAV cis vector

 Dual-promoter shRNA/miRNA rAAV cis vector

             Promoterless
             CMV
             CAG
             H1
            
U6
             Synapsin
             UBC

             EF1α
             ALB(1.4)
             ApoE/AAT1
             CaMKII
             ELA1
             Enh358MCK
             cTNT
             GFAP
             MBP
             SST
             TBG

             αMHC
             hRPE
             mIP1
             tMCK





















 

             Promoterless
             CMV
             CAG
             H1
            
U6
             Synapsin
             UBC

             EF1α
             ALB(1.4)
             ApoE/AAT1
             CaMKII
             ELA1
             Enh358MCK
             cTNT
             GFAP
             MBP
             SST
             TBG

             αMHC
             hRPE
             mIP1
             tMCK

  CMV
  CAG
  H1
 
U6
  Synapsin
  UBC

  EF1α
  CaMKII
  cTNT
  GFAP











 

eGFP
RFP
mRFP
mCherry
tdTOMATO
TurboGFP
eYFP
Venus
Luc
LacZ











 

 
  For CRISPR/Cas9 rAAV Production

 Single-promoter CRISPR/Cas9 AAV cis vector

 Dual-promoter CRISPR/Cas9 AAV cis vector

      Promoterless
      U6
      H1
      CMV
      CAG
      CBH
      Synapsin
      UBC

      EF1α
      ALB(1.4)
      ApoE/AAT1
      CaMKII
      ELA1
      Enh358MCK
      cTNT
      GFAP
      MBP
      SST
      TBG

      αMHC
      hRPE
      mIP1
      tMCK

  Empty
  CBH
  U6
  H1
  sCMV
  Syn
  sEF1α
  CK 0.4
  cTNT
  GFAP 0.6
  sSyn
  SST
  TBG
  αMHC
  hRPE
  mIP1
  tMCK
  CBH

Cas9
hCas9

SpCas9
hSpCas9
SaCas9
AsCpf1
hAsCpf1
ftCas9
st1Cas9
cjCas9
cdCas9
ciCas9
ncCas9
st3Cas9
nmCas9
mgCas9
nsCas9

 

      Promoterless
      sCMV
      U6
      H1
      tRNA
      Syn
      sSyn
     
sEF1α
      CaMKII 0.4

  CMV
  sCMV
  CBH
  H1
 
U6
  Syn
  sSyn

  sEF1α
  CaMKII 0.4





 

Cas9
hCas9

SpCas9
hSpCas9
SaCas9
AsCpf1
hAsCpf1
ftCas9
st1Cas9
cjCas9
cdCas9
ciCas9
ncCas9
st3Cas9
nmCas9
mgCas9
nsCas9


 


Service Description:
1. Synthesize and clone shRNA into AAV cis vectors.
2. Medium
scale transfection of AAV·HT™ 293 cell into 1xcell stack.
3. Harvest rAAV particle followed by
purification via advanced 2xCsCl ultra-centrifugation to obtain clinical trial grade of rAAV vector.
4. rAAV titration via qPCR.

rAAV Serotypes We Offer:
AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-PHP.B, AAV-PHP.eB, AAV-DJ/8 and AAV-DJ.

Required Materials: NCBI accession #, target sequence, validated siRNA or validated shRNA sequence; miRNA accession #, pre-miRNA, mature miRNA or TuD (tough decoy) miRNA.

Turnaround Time: 3 ~ 4 weeks.

Deliverables:
>0.2 mL super purified in vivo grade of rAAV vector at >1E+13 VG/mL*.

We offer discount for new customer, please request a quote with us today.

We also offer truncated custom shRNA/miRNA AAV service, please
request a quote with us today.
 


Figure 1. A comparison of purity and infectivity of rAAV vectors from different sources showing super purified and super infectious (close to clinical trial grade) rAAV vector prepared via our advanced double CsCl ultra-centrifugation approach. 
A. rAAV vectors (total 1E+9 VG per lane)  from different sources were resolved on SDS-PAGE followed by silver staining.  Lane 1: GMP manufactured rAAV vector from CHOP; Lane 2: rAAV prepared via our advanced 2xCsCl ultra-centrifugation approach; Lane 3: rAAV from Vector Core of BCM; Lane 4: rAAV from our competitor "V"; Lane 5: rAAV from our competitor "C"; Lane 6: Protein marker.
B. Super infectious rAAV vector prepared via advanced double CsCl ultra-centrifugation.  Left panel: rAAV9-GFP (total 5E+9 VG) from our competitor "V" injected to mouse eye; Right panel: rAAV-9-GFP (total 5E+9 VG) purified via advanced 2xCsCl ultra-centrifugation injected to mouse eye. 



Figure 2. A comparison of infectivity of rAAV vectors from different sources showing super purified rAAV prepared via advanced double CsCl ultra-centrifugation approach is super infectious.
rAAV1-GFP (total 2E+9 VG) from different sources were injected to mouse muscle tissue.  The GFP fluorescence was visualized 3 weeks post injection.  A. rAAV1-GFP from our competitor "V"; B. rAAV1-GFP from our pre-made rAAVs stock purified via advanced double CsCl ultra-centrifugation.  C. Quantification data showed that our super purified rAAV (bar 2) is ~ 9 times more infectious than that (bar 1) prepared via conventional CsCl ultra-centrifugation.  


* Final viral yield may depend on the nature of transgene.  
 




Copyright © 2017 SignaGen Laboratories. All Rights Reserved.